Michael Leonard Ritchey
Michael Leonard Ritchey (born December 27, 1954) is an American pediatric urologist and academic researcher known for his contributions to the treatment of Wilms' tumor.[1][2] He previously served as Chief Medical Officer at Phoenix Children’s Hospital.[3][4]
Early life and education
[edit]Ritchey completed his undergraduate degree at the University of Southwestern Louisiana in 1975 and earned his M.D. from Louisiana State University School of Medicine in 1979.[5] He completed his residency at Wilford Hall USAF Medical Center and a fellowship in pediatric urology at the Mayo Clinic.[6]
Career
[edit]He began his career in the United States Air Force, receiving the Meritorious Service Medal for his contributions.[7] He later held academic positions at the University of Michigan[2] and the University of Texas Medical School,[2] where he directed the Division of Urology. Since 2011, Ritchey has been affiliated with Phoenix Children’s Hospital, becoming Chief Medical Officer in 2018.
He was the contributor to the National Wilms Tumor Study Group,[8] played a key role in modern treatment protocols for this pediatric kidney cancer. His contributions extend to clinical guidelines that have improved outcomes for children globally. With over 200 peer-reviewed publications,[8] book chapters, and editorials.[3]
Research and publications
[edit]Ritchey has contributed to pediatric oncology research, including work with the National Wilms Tumor Study Group.[8] His publications focus on nephroblastoma, pediatric urology, and long-term outcomes of childhood cancer treatments. He has served on editorial boards, including the Journal of Urology.[8][9][5]
References
[edit]- ^ "Leadership Team". Phoenix Children's Hospital. Retrieved 2025-04-24.
- ^ a b c "Urology Research | University of Michigan Medical School". medschool.umich.edu. Retrieved 2025-04-24.
- ^ a b "Michael L. Ritchey". Scilit. Retrieved 8 May 2025.
- ^ Green, D. M.; Breslow, N. E.; Beckwith, J. B.; Ritchey, M. L.; Shamberger, R. C.; Haase, G. M.; D'Angio, G. J.; Perlman, E.; Donaldson, M.; Grundy, P. E.; Weetman, R.; Coppes, M. J.; Malogolowkin, M.; Shearer, P.; Coccia, P. (2001-09-01). "Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group". Journal of Clinical Oncology. 19 (17): 3719–3724. doi:10.1200/JCO.2001.19.17.3719. ISSN 0732-183X. PMID 11533093.
- ^ a b "Michael L. Ritchey. Pediatric Medalist 2019. Section on Urology American Academy of Pediatrics" (PDF). spuonline.org. Retrieved 2025-04-28.
- ^ "Michael L. Ritchey | Wilford Hall Medical Center | 1 Publications | 20 Citations | Related Authors". SciSpace - Author. Retrieved 2025-04-24.
- ^ https://www.jpurol.com/article/S1477-5131(20)30012-7/pdf
- ^ a b c d Ritchey, Michael L.; Shamberger, Robert C.; Hamilton, Thomas; Haase, Gerald; Argani, Pedram; Peterson, Susan (October 2005). "Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group". The Journal of Urology. 174 (4 Pt 2): 1519–1521, discussion 1521. doi:10.1097/01.ju.0000179536.97629.c5. ISSN 0022-5347. PMID 16148643.
- ^ Grundy, Paul E.; Breslow, Norman E.; Li, Sierra; Perlman, Elizabeth; Beckwith, J. Bruce; Ritchey, Michael L.; Shamberger, Robert C.; Haase, Gerald M.; D'Angio, Giulio J.; Donaldson, Milton; Coppes, Max J.; Malogolowkin, Marcio; Shearer, Patricia; Thomas, Patrick R. M.; Macklis, Roger (2005-10-10). "Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group". Journal of Clinical Oncology. 23 (29): 7312–7321. doi:10.1200/JCO.2005.01.2799. ISSN 0732-183X. PMID 16129848.
| Authority control databases: Academics |
|---|
